Food and Staples Retailing Drug Retail

More

  • All-American Pot Shop Chain?

    Jamen Shively, a former Microsoft executive and currently CEO of Diego Pellicer, wants to build the first national marijuana store brand.

  • Rise In Melanoma Treatments

    CNBC's Jackie DeAngelis reports on drug companies making headlines out of the American Society of Clinical Onocology conference. David Risinger of Morgan Stanley discusses the rise in melanoma treatments shown at this year's event.

  • A hospital epidemiologist and a geneticist at the National Institutes of Health Clinical Center in Bethesda, Md.

    Government officials, drug companies and medical experts, faced with outbreaks of antibiotic-resistant "superbugs", are pushing to speed up the approval of new antibiotics, the NYT reports.

  • A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.

  • Faber Report: Royalty Pharma to Raise Elan Bid

    A break down on the latest activity in mergers and acquisitions, with CNBC's David Faber.

  • What's Working in Pharma

    Of the new drugs approved from 2004 through 2011, Quintiles was involved with 85 percent of the central nervous system drugs, 76 percent of oncology drugs and 72 percent of cardiovascular drugs. Mad Money host Jim Cramer explains why the stock is a buy.

  • Talking Numbers: Pfizer Flops Earnings

    Technical analyst Jeff Tomasulo is bearish on Pfizer after its big drop today. Fundamental analyst Pat Dorsey also isn't a buyer. (2:25)

  • Novartis Disputes Allegations

    CNBC's Andrea Day reports Swiss drug maker Novartis is disputing allegations in 2 U.S. federal lawsuits. The company is accused of wining and dining doctors.

  • Isis Takes on Huntington's Disease

    Isis Pharmaceuticals CEO Stanley Crooke discusses his new technology Antisense and its role in helping huntington's disease.

  • Johnson & Johnson products

    The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.

  • Cheerios

    The "astonishing" growth of the middle class in emerging markets is benefiting General Mills and creating jobs in the U.S., CEO Ken Powell told CNBC's "Street Signs" on Thursday.

  • Red Hot Big Pharma Worth Owning

    Not every stock needs to have a "turbo-charged" growth angle to it. Mad Money host Jim Cramer says big pharma stocks have been red hot, and discusses which ones are worth owning.

  • Johnson & Johnson, a Break-Up Play?

    Investors should always have a high yielding stock in their portfolio. Big pharma stocks tend to do better when the economy isn't doing so well, explains Mad Money host Jim Cramer. A preview of Johnson & Johnson ahead of earnings.

  • Johnson & Johnson Hits All-Time High

    Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.

  • Biogen IDEC CEO on Multiple Sclerosis Pill

    Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.

  • Pay For Generic Drug Delay

    The government says big pharma should not be allowed to pay generic drug makers to let them keep their costly branded drugs on the market longer, reports CNBC's Bertha Coombs.

  • Mixed Session For Generic Drugmakers

    CNBC's Seema Mody reports the latest from the Nasdaq: Drug makers Actavis and AstraZeneca reach an agreement to launch a Crestor generic in 2016.

  • AstraZeneca Settles Patent Dispute

    AstraZeneca settled a patent dispute with generic drug maker Watson Laboratories over its cholesterol drug Crestor, reports CNBC's Bertha Coombs.

  • One sector that is yet to be truly tapped in Africa is the brewing industry, according to research firm Bernstein Research, which believes it is probably the most attractive region for long-term profit growth for global brewers.

  • Walgreens

    Sometimes, when a stock surges on an analyst upgrade, it's high time to make a bearish bet. That's exactly what one big options trader did on Walgreen.